Research

Mixed

Metabolic and bariatric surgery (MBS) provides significantly greater reduction in major adverse cardiovascular events (MACE) and all-cause mortality compared to GLP-1 receptor agonist (GLP-1 RA) therapy in patients with obesity and type 2 diabetes.

If you have obesity and type 2 diabetes, metabolic surgery (like gastric bypass or sleeve gastrectomy) is currently shown to be more effective than GLP-1 medications (like semaglutide or liraglutide) at preventing heart attacks, strokes, and death. While GLP-1 drugs are important for those who cannot have surgery, surgery offers greater long-term cardiovascular protection and more sustained weight loss, though it carries surgical risks and requires lifelong nutritional monitoring.

ModerateSupportsMEDIUM confidence
Pooled analysis of eligible studies suggested that MBS offered greater reductions in both MACE and all-cause mortality than GLP-1 RAs therapy. The relative risk reduction for MACE was approximately 52% in favor of MBS.
Joshua Chadwick et al. · Obesity Surgery · 2026

Why this rating

Moderate certainty by GRADE criteria, but includes observational cohorts and heterogeneity (I² = 78.3%).

Source

Efficacy of Metabolic and Bariatric Surgery Compared with GLP-1 Receptor Agonist Treatment in Preventing Mortality and Major Adverse Cardiac Events Among Individuals with Obesity and Type 2 Diabetes: A Systematic Review and Meta-analysis

Joshua Chadwick et al. · Obesity Surgery · 2026

DOI 10.1007/s11695-026-08508-5

Meta-analysis · 11 studies
Read the paper
DOI resolved against Crossref · corpus check 2026-06-10

This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →